JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer.

MLA

Ramalingam, Suresh S., et al. “JASPER: Phase 2 Trial of First‐line Niraparib plus Pembrolizumab in Patients with Advanced Non–small Cell Lung Cancer.” Cancer (0008543X), vol. 128, no. 1, Jan. 2022, pp. 65–74. EBSCOhost, https://doi.org/10.1002/cncr.33885.

APA

Ramalingam, S. S., Thara, E., Awad, M. M., Dowlati, A., Haque, B., Stinchcombe, T. E., Dy, G. K., Spigel, D. R., Lu, S., Iyer Singh, N., Tang, Y., Teslenko, I., & Iannotti, N. (2022). JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer. Cancer (0008543X), 128(1), 65–74. https://doi.org/10.1002/cncr.33885

Chicago

Ramalingam, Suresh S., Eddie Thara, Mark M. Awad, Afshin Dowlati, Basir Haque, Thomas E. Stinchcombe, Grace K. Dy, et al. 2022. “JASPER: Phase 2 Trial of First‐line Niraparib plus Pembrolizumab in Patients with Advanced Non–small Cell Lung Cancer.” Cancer (0008543X) 128 (1): 65–74. doi:10.1002/cncr.33885.